Neuron-Specific Enolase (NSE), Spinal Fluid
Use
The Neuron-Specific Enolase (NSE), Spinal Fluid test is used as an auxiliary diagnostic tool for Creutzfeldt-Jakob disease (CJD) and to detect small cell lung carcinoma metastasis to the central nervous system or leptomeninges. NSE is a gamma-homodimer isoenzyme found predominantly in neuronal and neuroendocrine tissues. Its concentration in cerebrospinal fluid (CSF) becomes elevated during rapid neuronal destruction, as frequently observed in progressive dementias such as CJD and in metastatic conditions involving the CNS. Therefore, NSE measurement helps in differentiating these conditions.
Special Instructions
Not provided.
Limitations
The diagnosis of CJD involves a combination of clinical history, examination, and tests, including EEG and MRI. NSE results need to be interpreted within the broader clinical context. Artifactual elevations can arise from hemolysis, interference by hemolytic anemia, hepatic failure, or end-stage kidney failure. Proton pump inhibitor treatments and certain neurological conditions may cause false positives. The test has limited prognostic value for coma patients.
New York Approved
Methodology
Immunoassay (Homogeneous Time-Resolved Fluorescence)
Biomarkers
Neuron-Specific Enolase
Protein
LOINC Codes
- 44802-7 - NSE CSF-mCnc
- 44802-7 - NSE CSF-mCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.3 mL
Container
Sterile vial
Causes for Rejection
Gross hemolysis, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 15 days |